Quantum Biopharma Signs an Agreement With Ingenu CRO to Conduct a Clinical Study to Observe Disease Progression in Patients With Primary Progressive Multiple Sclerosis

AccesswireSep 9 19:30

Quantum BioPharma Ltd. (QNTM) Announces Key Milestones; Price Target $12.80

AccesswireAug 30 22:30

Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update

AccesswireAug 24 07:30

FSD Pharma Completes Name Change to Quantum BioPharma and 65:1 Consolidation - Trading Under New Ticker Symbol "QNTM"

newsfileAug 15 18:00